Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights
Loading...All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
The interleukin-2 receptor subunit gamma (IL2RG) is a 42–75 kDa type I glycoprotein of the cytokine receptor superfamily. The mature protein includes an extracellular region with a fibronectin type III domain and a cytokine receptor homology module, single transmembrane helix and intracellular tail containing the Box 1/Box 2 motifs required for Janus kinase (JAK) docking. The intracellular domain has no intrinsic enzymatic activity but acts as a critical docking site so that JAK3 will bind and then phosphorylate tyrosine residues on the receptor after cytokines bind to start signaling downstream. It combines with ligand-specific alpha and beta chains to produce the functional receptors of at least six different interleukins, including IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. This common usage provides a basis for how mutations in an individual gene can POTENTIATE multiple cytokine signaling pathways. The receptor complexes are expressed on the surface of developing and mature lymphocytes, where they dictate growth, survival and differentiation. The IL-2RG is particularly interesting as it can exist in three forms: a high affinity heterotrimer (αβγ), an intermediate-affinity heterodimer (βγ) and a low-affinity monomer (α); the γc-containing βγ dimer mediates most of IL-2 signaling in activated T cells.
Fig.1 Schematic overview of common γ-chain (IL2RG/CD132)-dependent cytokine receptor signaling.1
IL2RG functional scope spans a variety of interconnected immunological domains:
We acknowledge that the type I cytokine receptor topology, numerous disulfide links and especially JAK3-interaction demands of IL2RG provide unique hurdles for its production. In this study, we discuss how multiple expression systems are employed to generate full-length IL2RG constructs that are well-folded, glycosylated, bind to native cytokine and transduce JAK3. Contains full-length membrane-bound receptor, soluble extracellular domain fragments and the IL2RG-IL2RB heterodimere complex. The methodology offers high reproducibility to enable biophysical validation of all preparations for suitability on not only structural studies but also ligand binding assay and antibody screenings.
Not finding the membrane protein product you need? Contact us to start your one-stop custom service!
The inability to quickly generate reliable, reproducible cellular models for dissecting IL2RG-driven biology and validating therapeutic candidates is a barrier to progress. Our stable cell lines were generated to express wild-type or disease-associated alleles of mouse and rat IL2RG in addition to modulating endogenous expression for loss-of-function studies. Optimized for high-throughput JAK-STAT reporter assays, T-cell proliferation studies, and in vitro analysis of other types of cytokine signaling pathways and gene therapy vector potency quantification, these platforms provide experimental consistency to support multi-phase research initiatives.
Not finding the stable cell line product you need? Contact us to start your one-stop custom service!
We offer IL2RG secndry antibodies with high affinity recombinant antibodies portfolio that are tailored to meet the high standards of various research needs. Using advanced recombinant technologies, these antibodies are designed to be more specific, sensitive and consistent from batch to batch than traditional polyclonal antibodies. Our IL2RG recombinant antibody have been validated for use in Western Blotting (WB), ELISA, Flow Cytometry (FCM), Immunofluorescence (IF), Immunocytochemistry(ICC) and Immunohistochemistry(IHC) and immunoprecipitation with the ability to accurately detect & quantify IL2RG from different sample types.
Not finding the recombinant antibody product you need? Contact us to start your one-stop custom service!
In addition to catalog products, we provide customized services for the discovery and development of membrane protein/antibodies. On the basis of our deep knowledge within cytokine receptor signaling and immunodeficiency, we aim to help you with:
No, all IL2RG products and services are strictly for research use only and are not intended for clinical diagnosis, prevention, treatment, or cure of any disease.
Absolutely. Our cell engineering team extrapolates a number of tetracycline-inducible systems and lines co-expressing IL2RG with JAK3, STAT5 or cytokine-specific alpha chains (IL-7Rα, IL-4Rα) for complete signaling studies on the regular. Let's have will discuss to or your desired expression architecture basis and phenotypic.
We provide human, mouse and rat IL2RG reagent in our catalogue. Production of additional orthologs or engineered mutants, e.g. JAK3-binding deficient variants, and patient-specific X-SCID mutations, as well as codon optimized constructs can be obtained on request.
Yes. We offer flexible pricing tiers to meet your academic and industrial scale-up needs. In order for us to provide you with your own specific quote, please enter the details of your projected volume and timeline into our inquiry portal.
